Oxazepam pharmacokinetics in thyroid disease

Area of Science:

• Pharmacology
• Endocrinology
• Drug Metabolism

Background:

• Oxazepam is primarily eliminated through glucuronidation.
• Thyroid hormone levels can influence drug metabolism.
• Understanding pharmacokinetic changes in thyroid dysfunction is crucial for safe drug prescribing.

Purpose of the Study:

• To investigate the impact of hyperthyroidism and hypothyroidism on the pharmacokinetics of oxazepam.
• To assess changes in oxazepam elimination half-life, oral clearance, and time to peak concentration in patients with thyroid dysfunction.
• To explore the relationship between thyroid status, serum bilirubin, and oxazepam metabolism.

Main Methods:

• Pharmacokinetic study involving seven hyperthyroid and six hypothyroid patients.
• Measurements taken before and after treatment to normalize thyroid function.
• Analysis of oxazepam elimination half-life, apparent oral clearance, and time to peak concentration (tmax).
• Serum bilirubin levels were also monitored.

Main Results:

• Hyperthyroid patients exhibited a shorter oxazepam elimination half-life and higher oral clearance compared to post-treatment levels.
• Time to peak concentration (tmax) was reduced in hyperthyroid patients.
• No significant changes in oxazepam elimination or tmax were observed in hypothyroid subjects.
• Serum bilirubin was lower in hyperthyroid patients before treatment.

Conclusions:

• Glucuronyl transferase activity appears to be increased in hyperthyroidism, leading to faster oxazepam metabolism.
• Hypothyroidism does not significantly alter oxazepam pharmacokinetics in most patients.
• The observed increase in enzyme activity in hyperthyroidism is comparable to that induced by certain drugs.